What is HC Wainwright’s Forecast for VRDN FY2024 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at HC Wainwright boosted their FY2024 EPS estimates for Viridian Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($3.96) per share for the year, up from their previous forecast of ($4.02). HC Wainwright has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.01) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2024 earnings at ($0.99) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($0.99) EPS and FY2025 earnings at ($4.06) EPS.

Several other equities analysts have also recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, November 13th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Royal Bank of Canada restated an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, September 19th. BTIG Research increased their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a research report on Monday, July 29th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $20.34 on Monday. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 15.82. The company’s 50-day moving average is $22.76 and its 200 day moving average is $17.06. The stock has a market capitalization of $1.61 billion, a P/E ratio of -4.72 and a beta of 1.10.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Viridian Therapeutics by 5.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock valued at $33,979,000 after acquiring an additional 81,951 shares during the period. Barclays PLC grew its stake in Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after buying an additional 66,550 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Viridian Therapeutics during the 3rd quarter worth $660,000. Sphera Funds Management LTD. purchased a new position in Viridian Therapeutics during the 3rd quarter worth $1,959,000. Finally, Point72 Asset Management L.P. purchased a new position in Viridian Therapeutics during the 3rd quarter worth $788,000.

Insider Buying and Selling at Viridian Therapeutics

In other news, CEO Stephen F. Mahoney acquired 21,400 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now directly owns 21,400 shares of the company’s stock, valued at $499,262. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fairmount Funds Management Llc purchased 1,600,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the purchase, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. This trade represents a 86.68 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 1,626,400 shares of company stock worth $30,616,312. Insiders own 0.65% of the company’s stock.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.